http://www.thedoctorschannel.com/video/3614.html

NEW YORK (Reuters Health) – The combination of the dipeptidyl peptidase (DPP)-4 inhibitor alogliptin and the thiazolidinedione pioglitazone effectively reduces HbA1c in patients with type 2 diabetes uncontrolled by diet and exercise, and a multicenter study shows.

The catch is that alogliptin is yet to be approved by the US Food and Drug Administration. Reports say that may not be until 2013.

Meanwhile, Dr. Julio Rosenstock with the Dallas Diabetes and Endocrine Center at Medical City, Texas, conducted a 26-week trial with 655 patients with type 2 diabetes who had not had prior drug treatment. They were randomly assigned to alogliptin 25 mg/d monotherapy, pioglitazone 30 mg/d monotherapy, or pioglitazone 30 mg/d in combination with alogliptin 12.5 mg/d or 25 mg/d.